Fakiha Siddiqui

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Fakiha Siddiqui, Alfonso Tafur, Lorenzo Storino Ramacciotti et al. · Clinical and Applied Thrombosis/Hemostasis · 2019 · 37 citations · Full text

Immunohematology, Differential Neutralization, Andexanet Alfa +23

Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling

Emily Bontekoe, Yevgeniy Brailovsky, Debra Hoppensteadt et al. · Clinical and Applied Thrombosis/Hemostasis · 2021 · 32 citations · Full text

The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper

Grigoris Gerotziafas, M. Catalano, Yiannis Theodorou et al. · Thrombosis and Haemostasis · 2021 · 31 citations · Full text

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Fakiha Siddiqui, Debra Hoppensteadt, Walter Jeske et al. · Clinical and Applied Thrombosis/Hemostasis · 2019 · 28 citations · Full text

Prothrombin Time, Rivaroxaban Does, Thrombin Generation Studies +19

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

Fakiha Siddiqui, Alfonso Tafur, Emily Bontekoe et al. · Clinical and Applied Thrombosis/Hemostasis · 2020 · 24 citations · Full text

Andexanet Alfa, Pharmacotherapy, Thrombosis +21